Search Results - "Massuti, T."

Recommendations in the management of epithelial appendiceal neoplasms and peritoneal dissemination from mucinous tumours (pseudomyxoma peritonei) by Barrios, P., Losa, F., Gonzalez-Moreno, S., Rojo, A., Gómez-Portilla, A., Bretcha-Boix, P., Ramos, I., Torres-Melero, J., Salazar, R., Benavides, M., Massuti, T., Aranda, E.

“…The epithelial appendiceal neoplasms are uncommon and are usually detected as an unexpected surgical finding. The general surgeon should be aware of the…”
Get full text

Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin by Losa, F., Barrios, P., Salazar, R., Torres-Melero, J., Benavides, M., Massuti, T., Ramos, I., Aranda, E.

“…Peritoneal carcinomatosis (PC) is a common form of tumour metastasis stemming from gastrointestinal and colorectal cancers. For a long time, PC has been…”
Get full text

Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial by Aranda, E., Cervantes, A., Carrato, A., Fern´ndez-Martos, C., Antón-Torres, A., Massutí, T., Barneto, I., García-Conde, J., Barón, J. M, Díaz-Rubio, E.

“…Background: Background: In a previous phase I–II trial we showed that maximum tolerable dose (MTD) of 5-fluorouracil (5-FU) a weekly 48-hour continuous…”
Get full text

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study by Aranda, E., Díaz-Rubio, E., Cervantes, A., Antón-Torres, A., Carrato, A., Massutí, T., Tabernero, J. M., Sastre, J., Trés, A., Aparicio, J., López-Vega, J. M., Barneto, I., García-Conde, J.

“…Purpose The objective of this multicenter study was to compare the efficacy and toxicity profiles of a combination of 5-fluorouracil (5-FU) given by bolus…”
Get full text

PD-042 Induction (I) or consolidation (C) chemotherapy withdocetaxel (D) and gemcitabine (G) plus concomitant chemoradiotherapy (CT/TRT) with docetaxel and carboplatin (Cb) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Initial report of the randomized phase II trial SLCG 0008 by Garrido, P., Resell, R., Arellano, A., Ramos, A., Massuti, T., Andreu, J., Cardenal, F., Arnaiz, A., Amador, M., Alberola, V.

Get full text

UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients by Díáz-Rubio, E, Sastre, J, Abad, A, Navarro, M, Aranda, E, Carrato, A, Gallén, M, Marcuello, E, Rifá, J, Massuti, T, Cervantes, A, Antón, A, Fernández Martos, C

“…Two studies were carried out to determine the activity and evaluate the toxicity of oral chemotherapy with uracil and tegafur in a 4:1 molar ratio (UFT) plus…”
Get more information

The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD) by Aranda, E, Cervantes, A, Carrato, A, Antón-Torres, A, Massutí, T, Fernández-Martos, C, Díaz-Rubio, E

“…Background In a previous phase I to II trial, we have shown that the maximum tolerable dose (MTD) of 5-Fluorouracil (5-FU) in 48-hour continuous infusion (CI)…”
Get more information

Concomitant chemoradiation plus induction (I) or consolidation (C) chemotherapy (CT) with docetaxel (D) and gemcitabine (G) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Results of the randomized SLCG 0008 phase II trial by Garrido, P., Massutí, T., Morán, T., Cardenal, F., Juan, O., Dómine, M., Cobo, M., García, R., Maestu, I., Isla, D.

“…Abstract only 7620 Background: Neither the optimal sequence of treatment nor the best combination CT is yet well-defined in p receiving concomitant therapy…”
Get full text

Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) by Aranda, E, Cervantes, A, Carrato, A, Fernández-Martos, C, Antón-Torres, A, Massutí, T, Barneto, I, García-Conde, J, Barón, J M, Díaz-Rubio, E

“…In a previous phase I-II trial we showed that the maximum tolerable dose (MTD) of 5-fluorouracil (5-FU) in a weekly 48-hour continuous infusion (CI) was 3.5…”
Get full text